Genentech presents Columvi sBLA for DLBCL treatment to FDA Advisory Committee for review.

From Nasdaq: 2025-05-20 23:16:00

Genentech discussed the sBLA for Columvi in combination with GemOx for DLBCL at the FDA Oncologic Drugs Advisory Committee. The FDA’s decision is expected by July 20, 2025. The Phase III STARGLO results were debated for U.S. patient applicability, with additional data needed. The study enrolled 274 patients globally, with the majority outside of Asia. For more health news, visit rttnews.com. The views expressed are those of the author and do not necessarily reflect Nasdaq, Inc.



Read more at Nasdaq: Genentech : FDA Advisory Committee Reviews Columvi SBLA For DLBCL Treatment In Non-ASCT Candidates